Glycinebetaine

Glycinebetaine

SCHEMBL486141

CN(C)CCO.C[N+](C)(C)CC(=O)[O-]

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

BHMTBHMT2

The experimentally established mechanism targets of Glycinebetaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.50
BBOX1 O75936 4/20 0.41
KDM4E B2RXH2 1/20 0.36
ALOX15 P16050 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TSHR P16473 1/20 0.36
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
APEX1 P27695 1/20 0.34
SLC22A16 Q86VW1 1/20 0.33
CPT2 P23786 1/20 0.31
CPT1A P50416 1/20 0.31
MEN1 O00255 1/20 0.30
CYP2C19 P33261 1/20 0.30
RECQL P46063 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycinebetaine SCHEMBL665485 0.82 TSHR (0.46) BBOX1TSHRALDH1A1LMNAAPEX1
Glycinebetaine SCHEMBL4599013 0.80 BBOX1 (0.42) BBOX1TSHRALDH1A1LMNAAPEX1
Glycinebetaine SCHEMBL2803780 0.79 TSHR (0.53) BBOX1TSHRALDH1A1LMNAAPEX1
Glycinebetaine SCHEMBL8678519 0.79 TSHR (0.53) BBOX1TSHRALDH1A1LMNAAPEX1
Glycinebetaine SCHEMBL4900209 0.79
Betaine SCHEMBL31467313 0.79
Glycinebetaine SCHEMBL7739 0.79
Glycinebetaine SCHEMBL1580653 0.79 BBOX1 (0.40) BBOX1SMN1; SMN2TSHRALDH1A1LMNA
Glycinebetaine SCHEMBL1138405 0.77 DNM1 (0.54) MAPTBBOX1KDM4ETSHRALDH1A1
Glycinebetaine SCHEMBL7996911 0.77 DNM1 (0.54) MAPTBBOX1KDM4ETSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220177949-A1 METHODS OF RNA AMPLIFICATION ASURAGEN, INC. 2022-06-09 US claimed
US-11236384-B2 Methods of RNA amplification ASURAGEN, INC. (US) 2022-02-01 US claimed
EP-3914068-A1 COMPOSITIONS FOR TREATING CITRUS DISEASE AND PROMOTING YIELD INCREASE IN ROW CROPS Spogen Biotech Inc. (US) 2021-12-01 EP claimed
CN-113395898-A Compositions for treating citrus disease and promoting yield enhancement of row crops 斯波根生物技术公司 2021-09-14 CN claimed
US-20200255851-A1 COMPOSITIONS FOR TREATING CITRUS DISEASE AND PROMOTING YIELD INCREASE IN ROW CROPS GENISYS CREDIT UNION 2020-08-13 US claimed
WO-2020154387-A1 COMPOSITIONS FOR TREATING CITRUS DISEASE AND PROMOTING YIELD INCREASE IN ROW CROPS SPOGEN BIOTECH INC. (US) 2020-07-30 WO claimed
US-20200140923-A1 METHODS OF RNA AMPLIFICATION ASURAGEN, INC. 2020-05-07 US claimed
EP-3606347-A1 AGRICULTURAL COMPOSITIONS FOR IMPROVED CROP PRODUCTIVITY AND ENHANCED PHENOTYPES Spogen Biotech Inc. (US) 2020-02-12 EP claimed
US-20180325103-A1 AGRICULTURAL COMPOSITIONS FOR IMPROVED CROP PRODUCTIVITY AND ENHANCED PHENOTYPES SPOGEN BIOTECH INC. (US) 2018-11-15 US claimed
WO-2018187345-A1 AGRICULTURAL COMPOSITIONS FOR IMPROVED CROP PRODUCTIVITY AND ENHANCED PHENOTYPES SPOGEN BIOTECH INC. (US) 2018-10-11 WO claimed
WO-2018136404-A1 METHODS OF RNA AMPLIFICATION ASURAGEN, INC. (US) 2018-07-26 WO claimed
US-20220283149-A1 ALL-IN-ONE MOLECULAR DIAGNOSTICS DEVICE GMD BIOTECH, INC (KR) 2022-09-08 US disclosed
US-20220177949-A1 METHODS OF RNA AMPLIFICATION ASURAGEN, INC. 2022-06-09 US disclosed
US-11236384-B2 Methods of RNA amplification ASURAGEN, INC. (US) 2022-02-01 US disclosed
EP-3914068-A1 COMPOSITIONS FOR TREATING CITRUS DISEASE AND PROMOTING YIELD INCREASE IN ROW CROPS Spogen Biotech Inc. (US) 2021-12-01 EP disclosed
EP-2396426-A1 METHOD OF AMPLIFICATION OF GC-RICH DNA TEMPLATES Asuragen, INC. (US) 2011-12-21 EP disclosed
WO-2010110835-A1 PCR METHODS FOR CHARACTERIZING THE 5' UNTRANSLATED REGION OF THE FMR1 AND FMR2 GENES ASURAGEN, INC. (US) 2010-09-30 WO disclosed
US-20100243451-A1 PCR METHODS FOR CHARACTERIZING THE 5' UNTRANSLATED REGION OF THE FMR1 AND FMR2 GENES ASURAGEN, INC. 2010-09-30 US disclosed
WO-2010093552-A1 METHOD OF AMPLIFICATION OF GC-RICH DNA TEMPLATES ASURAGEN, INC. (US) 2010-08-19 WO disclosed
US-20100209970-A1 METHOD OF AMPLIFICATION OF GC-RICH DNA TEMPLATES ASURAGEN, INC. 2010-08-19 US disclosed